CytRx Corporation to Present at Biotech Showcase 2018

LOS ANGELES, Jan. 3, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice President of Business Development and Investor Relations, will present at Biotech Showcase 2018 on Tuesday, January 9th at 11:30 a.m. Pacific Time at the Hilton Union Square in San Francisco.

A live and archived webcast of the presentation will be available at https://event.webcasts.com/starthere.jsp?ei=1176766&tp_key=9aeade4816.

As previously announced, CytRx plans to present at the following future investor conferences:

BIO CEO & Investor Conference 2018
February 12-13, 2018 (exact date and time TBD)
New York Marriott Marquis Hotel, New York, NY

30^th Annual ROTH Conference
March 11-13, 2018 (exact date and time TBD)
The Ritz Carlton, Laguna Niguel, CA

Presentation dates and times, along with any links to potential webcasts, will be provided closer to the actual events.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical company specializing in research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. CytRx is also rapidly expanding its pipeline of ultra-high potency oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx's expertise in albumin biology and linker technology for the development of a new class of potential breakthrough anti-cancer therapies.  Aldoxorubicin, CytRx's most advanced drug conjugate, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to NantCell, Inc. 

Forward-Looking Statements

This press release contains forward-looking statements. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks and uncertainties relating to plans for regaining compliance with the Nasdaq rules and higher share price of our common stock; the ability of NantCell, Inc., to obtain regulatory approval for its products that use aldoxorubicin; the ability of NantCell, Inc., to manufacture and commercialize products or therapies that use aldoxorubicin; the amount, if any, of future milestone and royalty payments that we may receive from NantCell, Inc.; our ability to develop new ultra-high potency drug candidates based on our LADR^TM technology platform; and other risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx's most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact: 
Argot Partners
Michelle Carroll/Sean Augustine-Obi
(212) 600-1902 
[email protected]
[email protected]

SOURCE CytRx Corporation

Related Links

http://www.cytrx.com